Analytical Data
-
Gene name
CXCL4
- Application
-
Alternative Names
CXCL4；CXCL4；SCYB4；;Platelet factor 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02776
-
Expression Region
32-101aa
-
AA Sequence
EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRK ICLDLQAPLYKKIIKKLLES
-
Molecular Weight
78 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL4, also known as platelet factor 4 (PF4), is a CXC chemokine that plays a crucial role in various physiological and pathological processes, including inflammation, angiogenesis, and hematopoiesis. It is primarily secreted by activated platelets and is involved in the recruitment of immune cells to sites of injury or infection. Due to its multifaceted roles, CXCL4 has garnered significant interest in research related to cardiovascular diseases, cancer, and autoimmune disorders. The study of recombinant CXCL4 protein has been pivotal in understanding its structure-function relationships, interaction with receptors, and potential therapeutic applications. Recombinant forms of CXCL4 can be produced in various expression systems, allowing researchers to investigate its biological activities and develop potential therapeutic strategies. For instance, recent studies have highlighted CXCL4's ability to modulate immune responses and inhibit tumor growth, suggesting its promise as a novel biomarker or therapeutic agent. As research progresses, the recombinant CXCL4 protein is being evaluated in preclinical models and clinical trials, paving the way for new insights into its role in human health and disease. Overall, CXCL4 represents a fascinating subject of study within the field of chemokine research, with implications for targeted therapies in inflammatory and neoplastic conditions.
